StockData
MeiraGTx Holdings plc logo

MeiraGTx Holdings plc (MGTX) stock

MGTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/3065% below fair value
$8.46−0.28 (-3.20%)

Close on Nov 17, 2026Market cap $812.52MP/E 11.9Yield –

MeiraGTx price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

MeiraGTx's price to sales ratio was 2.3× on Nov 11, 2026, against 24.4× a year earlier. Over the last 5 years it ranged from 2.2× to 51.5×, with a median of 19.3×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20262.3×−21.0
2025Dec 31, 202523.3×−10.6
2024Dec 31, 202434.0×+25.1
2023Jan 31, 20238.8×+1.9
2022Dec 30, 20226.9×−44.6
2021Dec 31, 202151.5×+20.4
2020Dec 31, 202031.1×–

More MeiraGTx figures

See a number that looks wrong?